Filing Overview
Registrant: Eliem Therapeutics, Inc. (the request metadata identifies Climb Bio, Inc.; the filing itself names Eliem Therapeutics, Inc.). Form 8-K date: January 18, 2022. The filing reports unaudited year-end liquidity and provides clinical-development updates and expected milestones.
Financial Position and Metrics
- Unaudited cash, cash equivalents and marketable securities were approximately $160 million as of December 31, 2021.
- Management expected this liquidity to fund operations through late 2023.
- The filing does not provide revenue, net income, cash flow, margins, debt, operating expenses, or comparative-period financial results.
Material Developments and Outlook
- ETX-810: The Phase 2a diabetic peripheral neuropathic pain trial reached full enrollment. Enrollment continued in the lumbosacral radicular pain trial, with completion expected in the first half of 2022.
- Topline ETX-810 data were expected in the first half of 2022 for diabetic peripheral neuropathic pain and the second half of 2022 for lumbosacral radicular pain.
- Phase 2b dose-ranging trials for ETX-810 were planned for the second half of 2022 and the first half of 2023, respectively.
- ETX-155: The planned fourth-quarter 2021 IND submission for major depressive disorder and perimenopausal depression was delayed after identification of an uncharacterized metabolite. The company expected to submit an updated IND in the first quarter of 2022, subject to FDA review.
- Assuming FDA clearance, initial dosing in Phase 2a trials of ETX-155 for major depressive disorder and perimenopausal depression was expected in the first half of 2022, with topline data expected in the second half of 2023.
- Enrollment was ongoing in a Phase 1b photosensitive epilepsy study of ETX-155, with interim data expected in the first half of 2022.
- The company planned IND-enabling studies for its Kv7.2/3 channel opener program in 2022 and expected to provide a development update for its generalized-anxiety-disorder program later in 2022.
Risks, Contingencies, and Unusual Items
The reported milestones, regulatory submissions, clinical readouts, and funding runway are forward-looking statements and are not guarantees. Key risks include failure to demonstrate safety or efficacy; delays or inability to conduct clinical trials; regulatory review or approval delays; unanticipated metabolites or other development findings; uncertain development costs and capital sufficiency; intellectual-property risks; competition; economic conditions; and COVID-19 or other public-health impacts. The company specifically identified the uncharacterized ETX-155 metabolite as the reason for delaying the previously planned IND submission.
Investor Verification Items
- Verify the identity of the registrant, since the filing names Eliem Therapeutics, Inc., while the request metadata names Climb Bio, Inc.
- Confirm the audited December 31, 2021 cash and marketable-securities balance and subsequent cash usage in later filings.
- Assess whether the stated liquidity runway through late 2023 remains adequate relative to clinical-development spending and financing needs.
- Review subsequent filings for ETX-810 enrollment completion, topline results, and Phase 2b initiation.
- Review whether the ETX-155 IND was submitted and cleared, and monitor the metabolite characterization and clinical-trial timeline.
- Compare actual clinical, regulatory, and preclinical milestones with the expectations disclosed in this filing.